Neurocrine Biosciences Inc (NBIX) Valuation
Historical valuation analysis based on 500 data points (2024-09-26 to 2026-09-24)
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorder...
Neurocrine Biosciences Inc (NBIX) currently trades at a P/E ratio of 21.49 (historical range: 19.54–42.96, median: 32.89), placing it at the 5th percentile — cheap relative to its history, P/S ratio of 4.63 (range: 3.72–7.09, 9th percentile — cheap relative to its history).
Over the historical period (2024-09-26 to 2026-09-24), Neurocrine Biosciences Inc's P/E ratio has contracted by 21% over the observed period (from an average of 36.3 to 28.7).
Neurocrine Biosciences Inc trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 21.49 | 19.54 | 32.89 | 42.96 | 5th | cheap relative to its history |
| P/S Ratio | 4.63 | 3.72 | 5.33 | 7.09 | 9th | cheap relative to its history |
| FCF Yield | 0.06 | 0.03 | 0.04 | 0.06 | 95th | cheap relative to its history |
Neurocrine Biosciences Inc (NBIX) Valuation & P/E History
Neurocrine Biosciences Inc (NBIX) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry currently trading at $137.17 with a market capitalization of $13.9 billion. This page provides historical valuation analysis for NBIX based on 500 data points covering 2024-09-26 to 2026-09-24. The P/E ratio of 21.49 is below the historical median of 32.89, placing NBIX at the 5th percentile of its valuation range. The P/S ratio of 4.63 compares to a median of 5.33.
NBIX Valuation Metrics & Historical Range
The valuation table above shows Neurocrine Biosciences Inc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether NBIX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests NBIX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Neurocrine Biosciences Inc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is NBIX Overvalued or Undervalued?
Neurocrine Biosciences Inc trades well below its historical valuation range across most metrics. The overall valuation percentile of 7 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive NBIX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full NBIX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.NBIX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.